Aller directement au menu principal Aller directement au contenu principal Aller au pied de page

Cortica explique-moi

Vol. 2 No. 2 (2023): OPEN SCIENCE : Accès aux savoirs scientifiques auprès des professionnels de santé et contribuer à la littératie scientifique citoyenne

Psychedelics in therapy

  • Thomas Cardoso de Oliveira
  • Tommaso Portesan
  • Yelena Caloz
August 28, 2023


Psychedelics in therapy


  1. Bell, R. F., Eccleston, C., & Kalso, E. A. (2017). Ketamine as an adjuvant to opioids for cancer pain. The Cochrane Database of Systematic Reviews, 2017(6), CD003351.
  2. Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs : Past, Present, and Future. Neuropsychopharmacology, 42(11), 2105‑2113.
  3. Coyle, C. M., & Laws, K. R. (2015). The use of ketamine as an antidepressant : A systematic review and meta-analysis. Human Psychopharmacology: Clinical and Experimental, 30(3), 152‑163.
  4. Goodman, N. (2002). The Serotonergic System and Mysticism : Could LSD and the Nondrug-Induced Mystical Experience Share Common Neural Mechanisms? Journal of Psychoactive Drugs, 34(3), 263‑272.
  5. Grady, S. E., Marsh, T. A., Tenhouse, A., & Klein, K. (2017). Ketamine for the treatment of major depressive disorder and bipolar depression : A review of the literature. Mental Health Clinician, 7(1), 16‑23.
  6. Gregorio, D. D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021). Hallucinogens in Mental Health : Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. Journal of Neuroscience, 41(5), 891‑900.
  7. Hake, H. S., Davis, J. K. P., Wood, R. R., Tanner, M. K., Loetz, E. C., Sanchez, A., Ostrovskyy, M., Oleson, E. B., Grigsby, J., Doblin, R., & Greenwood, B. N. (2019). 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiology & Behavior, 199, 343‑350.
  8. Johnson, M. W., & Griffiths, R. R. (2017). Potential Therapeutic Effects of Psilocybin. Neurotherapeutics, 14(3), 734‑740.
  9. Kim, K., Che, T., Panova, O., DiBerto, J. F., Lyu, J., Krumm, B. E., Wacker, D., Robertson, M. J., Seven, A. B., Nichols, D. E., Shoichet, B. K., Skiniotis, G., & Roth, B. L. (2020). Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor. Cell, 182(6), 1574-1588.e19.
  10. Lewis-Healey, E., Laukkonen, R., & van Elk, M. (20220526). Future directions for clinical psilocybin research : The relaxed symptom network. Psychology & Neuroscience, 15(3), 223.
  11. Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264‑355.
  12. Orhurhu, V., Orhurhu, M. S., Bhatia, A., & Cohen, S. P. (2019). Ketamine Infusions for Chronic Pain : A Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesthesia & Analgesia, 129(1), 241.
  13. Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., & McDonald, W. M. (2020). Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry, 177(5), 391‑410.
  14. Studerus, E., Vizeli, P., Harder, S., Ley, L., & Liechti, M. E. (2021). Prediction of MDMA response in healthy humans : A pooled analysis of placebo-controlled studies. Journal of Psychopharmacology (Oxford, England), 35(5), 556‑565.
  15. Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs : Implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11(9), Article 9.